Identification of Small Molecule Inhibitors of the Deubiquitinating Activity of the SARS-CoV-2 Papain-Like Protease: in silico Molecular Docking Studies and in vitro Enzymatic Activity AssayChemistry Published on 2020-12-082022-10-31 Journal: Frontiers in Chemistry [Category] COVID-19, [키워드] activity Antiviral Antiviral effect approach binding binding site candidate canonical catalytic caused Characteristics cleave Compound compounds Consequences coronavirus COVID-19 Critical crystal structures deubiquitinase deubiquitinase inhibitors docking Effects enzymatic activity evaluate functional gallate high affinity Hypericin identification immune regulation in silico in vitro indicated inhibited inhibiting inhibitor inhibitors mechanism molecular docking molecule pandemic Papain-like protease polypeptides pp1a pp1ab protease Protease activity Protease inhibitor Proteases public health Replication SARS-CoV-2 Seven shown small molecule subsequent the SARS-CoV-2 the SARS-CoV-2 virus these compound trials [DOI] 10.3389/fchem.2020.623971 PMC 바로가기 [Article Type] Chemistry
Syncytia formation by SARS-CoV-2-infected cellsSARS-CoV-2에 감염된 세포에 의한 융합체 형성Article Published on 2020-12-012022-09-11 Journal: The EMBO Journal [Category] MERS, SARS, 바이오마커, 유전자 메커니즘, 진단, [키워드] ACE2 Antiviral effect cellular cellular mechanism contrary COVID-19 Effect ENhance Express extensive lung damage facilitate family FUSE fusion IFITM1 IFITM2 IFITM3 IFITMs increase infected cells inhibit interferon lung damage modulated neighboring cells Pneumocytes Protein restriction factor SARS-CoV-2 SARS-CoV-2-infected cell SARS-CoV-2-infected cells Serine serine protease severe cases Spike protein Syncytia syncytia formation the Spike TMPRSS2 transmembrane protein Trigger triggers Viral Viral protein Viral proteins virions viruses [DOI] 10.15252/embj.2020106267 PMC 바로가기 [Article Type] Article
Interferon-inducer antivirals: Potential candidates to combat COVID-19Review Published on 2020-12-012022-10-04 Journal: International immunopharmacology [Category] MERS, SARS, 신약개발, 치료제, [키워드] acute respiratory syndrome adverse effect Antibiotics Antiviral antiviral agent Antiviral effect antivirals approach benefit candidate category Compound compounds coronavirus Coronavirus disease 2019 COVID-19 database Defense disease drug drug candidate Drug repurposing effective evaluated examined help immune response immune system immunosuppressants induce infective interferon lack management mechanism non-steroidal anti-inflammatory drug pandemic Potential risk SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 Side effects signaling pathway Structure synergistic the interferon treating COVID-19 Treatment treatment for COVID-19 triggering Type type I interferon urgency [DOI] 10.1016/j.intimp.2020.107245 PMC 바로가기 [Article Type] Review
Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatmentResearch article Published on 2020-12-012022-10-05 Journal: European journal of pharmacology [Category] SARS, 신약개발, 유전자 메커니즘, 임상, 치료법, 치료제, [키워드] ACE2 acute respiratory syndrome Affect Analysis antiviral drug antiviral drugs Antiviral effect approved benefit Chloroquine clinical trials collected coronavirus Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients distribution distributions drug enzyme evaluate expression Favipiravir GI Tract Hydroxychloroquine Hypothesis inhibit inhibit SARS-CoV-2 intestine lung lung tissue patients profile profiles reduce reducing Remdesivir reported repurposing respiratory tract ribavirin RNA RNA sequencing SARS-CoV-2 Single Cell Stool tested Tissue distribution TMPRSS2 transmembrane treat Treatment umifenovir Viral load viral loads viral replication Viral RNA [DOI] 10.1016/j.ejphar.2020.173634 [Article Type] Research article
Ifit2 deficiency restricts microglial activation and leukocyte migration following murine coronavirus (m-CoV) CNS infectionResearch Article Published on 2020-11-302022-10-29 Journal: PLoS Pathogens [Category] Coronavirus, [키워드] absence accompanied Activation Antiviral effect Brain caused CD4 T cell cellular chemokine Chemokine receptor Clinical sign CNS contributing to coronavirus Coronavirus infection Critical CX3CL1 CX3CR1 cytokine deficiency develop dissemination expression functions IFN IFNs immune protection Infection infiltration interferon-induced protein ISG ISGs lack leukocyte mechanism mice microglial Migration morbidity and mortality murine Neurological deficit neurotropic NK1.1 Pathogenesis PROTECT protective mechanism Protein receptor recruitment reduced regulate restrict significantly Spread stimulated Symptom T cell tissue homeostasis viral clearance Viral load viral replication virus virus load virus replication viruses wild-type [DOI] 10.1371/journal.ppat.1009034 PMC 바로가기 [Article Type] Research Article
Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19Article Published on 2020-11-202022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, SARS, [키워드] activity acute respiratory distress acute respiratory syndrome Adverse drug reaction Antiviral effect Bioavailability Cell characterized clinical development co-morbidity coronavirus coronavirus disease COVID-19 COVID-19 drugs Cytokine storm demonstrated drug Drug development Efficacy exhibit highlighting increased risk Inflammation innate immune response joint inflammation mechanism Mild occurred older patient Organ failure oxidative stress pandemic physiological action polymorph Preclinical prevention reactive oxygen specy ROS safety profile SARS-CoV-2 scavenging similarity sodium stability syndrome systemic inflammatory response [DOI] 10.3390/ijms21228803 PMC 바로가기 [Article Type] Article
Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin아지트로마이신에 의한 인플루엔자 A 및 SARS-CoV-2 바이러스의 바이러스 침입에 대한 직접적인 억제 효과Original Article Published on 2020-11-192022-09-10 Journal: Cell Proliferation [Category] SARS, 신약개발, 치료제, [키워드] A549 cell alkalinization antiviral agent Antiviral agents Antiviral effect Azithromycin azithromycin treatment binding Caco2 cells cell line Direct Drug repurposing drugs effective inhibitor Emergency evaluate expression fusion IAV impair in vitro independent independent of Infection Influenza influenza A influenza A virus inhibit inhibited inhibitory effect interferon internalization lead luciferase reporter gene lysosomal material membrane fusion membranes objective pseudotyped Pseudotyped virus pseudovirus reported reporter reporter gene Result SARS‐CoV‐2 SARS‐CoV‐2 virus SARS‐CoV‐2 screened spike mutations Strains subtype Treatment vacuolar Vesicle vesicles Viral viral entry viral replication virions virus was used [DOI] 10.1111/cpr.12953 PMC 바로가기 [Article Type] Original Article
Phytochemicals: Potential Therapeutic Interventions Against Coronavirus-Associated Lung InjuryPharmacology Published on 2020-11-182022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute respiratory syndrome Against anti-inflammatory effect anti-SARS-CoV-2 Antiviral effect approved caused Complication complications Compound coronavirus coronavirus disease Coronaviruses COVID-19 COVID-19 infection died disease Evidence Inflammatory inhibitory effect involved Lung injury mechanism outbreak oxidative Pathogenesis pharmacological mechanism phytochemicals Potential reducing SARS-CoV-2 shown signaling pathway significant effect therapeutic agent Treatment [DOI] 10.3389/fphar.2020.588467 PMC 바로가기 [Article Type] Pharmacology
EGYVIR: An immunomodulatory herbal extract with potent antiviral activity against SARS-CoV-2Research Article Published on 2020-11-182022-10-28 Journal: PLoS ONE [Category] COVID-19, SARS, [키워드] acute respiratory syndrome antiviral activity antiviral agent Antiviral effect cell lines Combination coronavirus Cytokine storm Cytokines storm elements Huh-7 IL-6 immunomodulatory in vitro in vitro study in-silico In-vitro infection process NF-kβ nuclear translocation P50 pandemic pathway SARS-CoV-2 severe cases the disease the SARS-CoV-2 TNFα Vaccine virucidal [DOI] 10.1371/journal.pone.0241739 PMC 바로가기 [Article Type] Research Article
A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical NeedsPharmacology Published on 2020-11-172022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute respiratory syndrome alleviate anti-viral agents antiviral agent Antiviral effect Asymptomatic benefit blunt children China Chinese Chloroquine clinical clinical evidence clinical trial convalescent plasma coronavirus disease Coronavirus-2 COVID-19 COVID-19 patient Critical critical COVID-19 patient cytokine release Cytokine release syndrome drug early stage Efficacy Favipiravir highlight Hydroxychloroquine in vitro Inflammation inhibit inhibitor initial interferon interleukin-6 interleukin-6 inhibitors late stage Mild MOST Negative conversion non-randomized observational study pandemic Patient patients with COVID-19 Pediatric case Prophylaxis repurposing review ribavirin sample-size SARS-CoV-2 severe COVID-19 patient severe patients small sample size Study design therapeutic option therapy Traditional Chinese medicine Treatment treatment initiation with mild disease [DOI] 10.3389/fphar.2020.584956 PMC 바로가기 [Article Type] Pharmacology